TY - JOUR
T1 - Preventing cardiovascular disease in primary care
T2 - Role of a national risk factor management program
AU - McGrath, Emer R.
AU - Glynn, Liam G.
AU - Murphy, Andrew W.
AU - Conghaile, Aengus O.
AU - Canavan, Michelle
AU - Reid, Claire
AU - Moloney, Brian
AU - O'Donnell, Martin J.
N1 - Copyright © 2012 Mosby, Inc. All rights reserved.
PY - 2012/4
Y1 - 2012/4
N2 - Background: Heartwatch, a structured risk factor modification program for secondary prevention of cardiovascular (CV) disease (CVD) in primary care, is associated with improvements in CV risk factors in participating patients. However, it is not known whether Heartwatch translates into reductions in clinically important CV events. Objective: The aim of the study was to determine the association between participation in Heartwatch and future risk of CV events in patients with CVD. Methods: The study consisted of a prospective cohort of 1,609 patients with CVD in primary care practices. Of these, 97.5% had data available on Heartwatch participation status, of whom 15.2% were Heartwatch participants. Cox proportional hazards models were used to determine the association between Heartwatch participation and risk of the CV composite (CV death, nonfatal myocardial infarction, heart failure, and nonfatal stroke). All-cause mortality and CV mortality were secondary outcome measures. Results: During follow-up, the CV composite occurred in 208 patients (13.6%). Of Heartwatch participants, 8.4% experienced the CV composite compared with 14.5% of nonparticipants (P =.003). Participation in Heartwatch was associated with a significantly reduced risk of the CV composite (hazard ratio [HR] 0.52, 95% CI, 0.31-0.87), CV mortality (HR 0.31, 95% CI, 0.11-0.89), and all-cause mortality (HR 0.32, 95% CI, 0.15-0.68). Heartwatch participation was also associated with greater reductions in mean systolic blood pressure (P =.047), mean diastolic blood pressure (P <.001), and greater use of secondary preventative therapies for CVD, such as lipid-lowering agents (P <.001), β-blockers (P <.001), and angiotensin-converting enzyme inhibitors (P <.001). Conclusion: Heartwatch is associated with a reduced risk of major vascular events and improved risk factor modification, supporting its potential as a nationwide program for secondary prevention of CVD.
AB - Background: Heartwatch, a structured risk factor modification program for secondary prevention of cardiovascular (CV) disease (CVD) in primary care, is associated with improvements in CV risk factors in participating patients. However, it is not known whether Heartwatch translates into reductions in clinically important CV events. Objective: The aim of the study was to determine the association between participation in Heartwatch and future risk of CV events in patients with CVD. Methods: The study consisted of a prospective cohort of 1,609 patients with CVD in primary care practices. Of these, 97.5% had data available on Heartwatch participation status, of whom 15.2% were Heartwatch participants. Cox proportional hazards models were used to determine the association between Heartwatch participation and risk of the CV composite (CV death, nonfatal myocardial infarction, heart failure, and nonfatal stroke). All-cause mortality and CV mortality were secondary outcome measures. Results: During follow-up, the CV composite occurred in 208 patients (13.6%). Of Heartwatch participants, 8.4% experienced the CV composite compared with 14.5% of nonparticipants (P =.003). Participation in Heartwatch was associated with a significantly reduced risk of the CV composite (hazard ratio [HR] 0.52, 95% CI, 0.31-0.87), CV mortality (HR 0.31, 95% CI, 0.11-0.89), and all-cause mortality (HR 0.32, 95% CI, 0.15-0.68). Heartwatch participation was also associated with greater reductions in mean systolic blood pressure (P =.047), mean diastolic blood pressure (P <.001), and greater use of secondary preventative therapies for CVD, such as lipid-lowering agents (P <.001), β-blockers (P <.001), and angiotensin-converting enzyme inhibitors (P <.001). Conclusion: Heartwatch is associated with a reduced risk of major vascular events and improved risk factor modification, supporting its potential as a nationwide program for secondary prevention of CVD.
UR - http://www.scopus.com/inward/record.url?scp=84860148496&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2012.01.027
DO - 10.1016/j.ahj.2012.01.027
M3 - Article
C2 - 22520539
AN - SCOPUS:84860148496
SN - 0002-8703
VL - 163
SP - 714
EP - 719
JO - American Heart Journal
JF - American Heart Journal
IS - 4
ER -